Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Young Therapeutics LLC has 1 pending office action in Biotechnology & Pharmaceuticals. The matter involves 1 distinct examiner and 1 distinct art unit, indicating a focused prosecution record.
KONOPELSKI SNAVEL, SARA ELIZABETH is the busiest examiner and handles the pending matter. Practitioner effort can be directed toward one examiner’s expectations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17914147 | PROTEIN KINASE C MODULATORS | KONOPELSKI SNAVEL, SARA ELIZABETH | 8d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17914147 | PROTEIN KINASE C MODULATORS | KONOPELSKI SNAVEL, SARA ELIZABETH | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17914147 | PROTEIN KINASE C MODULATORS | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112 | Final Rejection | 8d overdue | Pending | Sep 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYoung Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sara Elizabeth Konopelski Snavel has the most, with 1 of Young Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
